Plasma HIV-1 RNA and CD4+ T-cell counts are determinants of virological non-suppression outcomes with initial integrase inhibitor-based regimens: A prospective RESPOND cohort study.
Hortensia ÁlvarezAmanda MocroftLene RyomBastian NeesgaardSimon EdwardsVero-Nica SvedhemHuldrych F GünthardRobert ZangerleColette SmithAntonella CastagnaAntonella D Arminio MonforteFerdinand WitMelanie StecherClara LehmanCristina MussiniEric FontasEva GonzálezJan-Christian WasmuthAnders SönnerborgStéphane De WitNikoloz ChkhartishviliChristoph StephanKathy PetoumenosNadine JaschinskiVani VannappagariJoel GallantLital YoungAlain Volny AnneLauren GreenbergRaquel Martín-IguacelEva PovedaJosep M Llibrenull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Initial high HIV-1 RNA and low CD4+ counts are associated with lower rates of VS at 48 and 96 weeks and higher rates of viral blips, LLV and RV. Low baseline CD4+ counts are associated with higher VF rates.These associations remain with INSTI- and specifically dolutegravir-based regimens. These findings suggest that the impact of these baseline determinants is independent of the ART regimen initiated.